Gynergène Caféiné (Ergotamine Tartrate, Caffeine)

Gynergène Caféiné is indicated for the acute treatment of migraine episodes in adults.

• Alleviation of moderate to severe migraine headache pain, including throbbing or pulsating sensations.
• Decrease of accompanying migraine symptoms such as nausea, vomiting, photophobia, and phonophobia.
• Shortening of the overall duration of an acute migraine attack when taken at onset.
• Option for patients who have not responded to or cannot use triptan medications.
• Use as a rescue therapy for breakthrough migraine episodes despite preventive treatment.

The safety profile of Gynergène Caféiné includes both frequent, less severe reactions and rare, potentially serious events.

Common

• Nausea or stomach discomfort.
• Dizziness or light‑headed feeling.
• Tingling, numbness, or paresthesia in the fingers or toes.
• Mild flushing, warmth, or feeling of pressure.
• Transient worsening of headache if the medication is not taken promptly.

Serious

• Severe vasoconstriction that may cause chest pain, cardiac ischemia, or peripheral ischemic events.
• Allergic reactions including rash, itching, swelling of the face, lips, or tongue, and difficulty breathing.
• Persistent vomiting, severe dehydration, or hypertensive crisis requiring medical attention.

Before prescribing Gynergène Caféiné, clinicians should evaluate several precautionary factors to ensure safe use.

• Evaluate cardiovascular disease; ergotamine may worsen coronary, peripheral, or cerebrovascular conditions.
• Check for hypertension or uncontrolled high blood pressure.
• Use cautiously in patients with liver or kidney impairment.
• Avoid during pregnancy or lactation unless benefits clearly outweigh risks.
• Do not prescribe to individuals with known ergot allergy or previous ergotism.
• Limit frequency to prevent medication‑overuse headache.

Gynergène Caféiné can interact with several medicines; awareness of these interactions helps prevent adverse effects.

Avoid

• Monoamine oxidase inhibitors (MAOIs) – risk of severe hypertension.
• Ergot derivatives (e.g., dihydroergotamine) – additive vasoconstriction.
• Certain antihypertensives (e.g., beta‑blockers) – may reduce therapeutic effect.

Use with caution

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole) – may increase ergotamine levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy.
• Other serotonergic agents (e.g., triptans, SSRIs) – potential for serotonin syndrome.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may increase risk of gastrointestinal irritation.